Showing results (21-30 of 154) with videos related to

Sort By:
Pageof 16
Pulmonary Circulation|April 19, 2019
Pharmacokinetic interaction of riociguat and antiretroviral combination regimens in HIV-1-infected adultsEdwin DeJesus, Soundos Saleh, Sue Cheng, et al.
AIDS Research and Therapy|April 11, 2009
A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study)Princy N Kumar, Patricia Salvato, Anthony LaMarca, et al.
Antiviral Therapy|August 17, 2010
Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adultsEdwin DeJesus, Jacob P Lalezari, Olayemi O Osiyemi, et al.
HIV Clinical Trials|December 4, 2010
A pilot study of abacavir/lamivudine and raltegravir in antiretroviral-naïve HIV-1-infected patients: 48-week results of the SHIELD trialBenjamin Young, Thanes Vanig, Edwin Dejesus, et al.
Antimicrobial Agents and Chemotherapy|November 19, 2008
Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adultsJeffrey M Jacobson, Daniel R Kuritzkes, Eliot Godofsky, et al.
HIV Clinical Trials|June 13, 2008
Once-daily abacavir/lamivudine and ritonavir-boosted atazanavir for the treatment of HIV-1 infection in antiretroviral-naïve patients: a 48-week pilot studyRichard Elion, Edwin Dejesus, Michael Sension, et al.
The Journal of Infectious Diseases|September 27, 2003
Valacyclovir for the suppression of recurrent genital herpes in human immunodeficiency virus-infected subjectsEdwin DeJesus, Anna Wald, Terri Warren, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 24, 2019
Once-daily Doravirine in Human Immunodeficiency Virus Type 1-Infected, Antiretroviral-naive Adults: An Integrated Efficacy AnalysisChloe Orkin, Jean-Michel Molina, Johan Lombaard, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 28, 2005
Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patientsMartin Markowitz, Christina Hill-Zabala, Joseph Lang, et al.
AIDS (London, England)|July 9, 2004
SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patientsJoseph C Gathe, Prudence Ive, Robin Wood, et al.
Pageof 16